Cargando…
Complement biomarkers reflect the pathological status of neuromyelitis optica spectrum disorders
Complement is involved in the pathogenesis of neuroimmune disease, but the detailed pathological roles of the complement pathway remain incompletely understood. Recently, eculizumab, a humanized anti-C5 monoclonal antibody, has been clinically applied against neuroimmune diseases such as myasthenia...
Autores principales: | Miyamoto, Katsuichi, Minamino, Mai, Kuwahara, Motoi, Tsujimoto, Hiroshi, Ohtani, Katsuki, Wakamiya, Nobutaka, Katayama, Kei-ichi, Inoue, Norimitsu, Ito, Hidefumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020620/ https://www.ncbi.nlm.nih.gov/pubmed/36936980 http://dx.doi.org/10.3389/fimmu.2023.1090548 |
Ejemplares similares
-
Evidence for classic complement activity in neuromyelitis optica
por: Jones, Melina V., et al.
Publicado: (2014) -
Worldwide Incidence and Prevalence of Neuromyelitis Optica: A Systematic Review
por: Papp, Viktoria, et al.
Publicado: (2021) -
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder
por: Yamashita, Kazuya, et al.
Publicado: (2018) -
Efficacy of the anti–IL-6 receptor antibody tocilizumab in neuromyelitis optica: A pilot study
por: Araki, Manabu, et al.
Publicado: (2014) -
Neuromyelitis Optica
por: Misra, M. C., et al.
Publicado: (1953)